Divarasib Beats Approved KRAS Inhibitors in Lung Cancer Frederik Joelving

https://www.medscape.com/viewarticle/divarasib-beats-approved-kras-inhibitors-lung-cancer-2026a10014jm?src= The investigational targeted therapy divarasib extends overall survival in patients with previously treated, advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC), outperforming two existing KRAS inhibitors, according to findings from the phase 3 Krascendo 1 trial.